Stiripentol open study in Japanese patients with Dravet syndrome

Authors: Inoue, Yushi¹; Ohtsuka, Yoko²; Oguni, Hirokazu³; Tohyama, Jun⁴; Baba, Hiroshi⁵; Fukushima, Katsuyuki⁶; Ohtani, Hideyuki¹; Takahashi, Yukitoshi¹; Ikeda, Shunya⁷

Source: Epilepsia, Volume 50, Number 11, November 2009 , pp. 2362-2368(7)

Publisher: Wiley-Blackwell

Abstract:

Summary Purpose: 

To survey the treatment situation of Dravet syndrome in Japan and to compare this result with effectiveness of stiripentol (STP) add-on therapy in an open-label multicenter study. Methods: 

Medical records of patients with Dravet syndrome who visited the study institutions during 2006 were surveyed to examine the effect of antiepileptic drugs (AEDs) on clonic or tonic-clonic seizures (GTCS). Patients older than 1 year of age treated with at least one conventional AED and more than four GTCS per month were invited to participate in the STP study. Seizure status and adverse effects during the first 4 weeks of STP (50 or 1,000 mg/day) add-on therapy (early period) and during long-term treatment were compared with baseline. Results: 

Only 15% of the treatment trials with 15 conventional AEDs in 112 patients succeeded in reducing seizures by more than 50%. With STP, GTCS were reduced more than 50% in 14 of 23 patients (61%), including 2 who became seizure-free, in the early period. Moreover, duration of seizures was shortened in 10 patients and status epilepticus decreased in 6. These effects continued in the long-term although to a lesser degree. Adverse effects (loss of appetite, sleep disturbance, ataxia, hyperactivity/irritability) disappeared after dose modification in most cases. STP was effective at a lower than initial dose in five patients. Some patients benefited from STP added on clobazam despite mutation in CYP2C19. Conclusion: 

Our data suggest that an early introduction of STP into Japan will result in substantial patient benefit.

Keywords: Severe myoclonic epilepsy in infancy; Dravet syndrome; Stiripentol; Clobazam; Cytochrome P450

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1528-1167.2009.02179.x

Affiliations: 1: Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan 2: Department of Child Neurology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan 3: Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan 4: Nishi-Niigata Chuo National Hospital, Niigata, Japan 5: Nagasaki Medical Center, Nagasaki, Japan 6: Yakumo Hospital, Hokkaido, Japan 7: Department of Pharmaceutical Sciences, International University of Health and Welfare, Tokyo, Japan

Publication date: 2009-11-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Neurology & Psychiatry
• By this author: Inoue, Yushi ;  Ohtsuka, Yoko ;  Oguni, Hirokazu ;  Tohyama, Jun ;  Baba, Hiroshi ;  Fukushima, Katsuyuki ;  Ohtani, Hideyuki ;  Takahashi, Yukitoshi ;  Ikeda, Shunya

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers